Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients

Kellie A. Charles¹, Benjamin D. W. Harris¹, Carol R. Haddad², Stephen J. Clarke³,⁴, Alex Guminski⁴, Mark Stevens²,³, Tristan Dodds⁵,⁶, Anthony J. Gill⁵,⁶, Michael Back²,³, David Veivers⁷ and Thomas Eade²,³*

Abstract

**Background:** Currently there are very few biomarkers to identify head and neck squamous cell carcinoma (HNSCC) cancer patients at a greater risk of recurrence and shortened survival. This study aimed to investigate whether a marker of systemic inflammation, the neutrophil-to-lymphocyte ratio (NLR), was predictive of clinical outcomes in a heterogeneous cohort of HNSCC cancer patients.

**Methods:** We performed a retrospective analysis to identify associations between NLR and clinicopathological features to recurrence free survival (RFS) and overall survival (OS). Univariate analysis was used to identify associations and selected variables were included in multivariable Cox regression analysis to determine predictive value.

**Results:** A total of 145 patients with stage I-IV HNSCC that had undergone radiotherapy were analysed. Seventy-six of these patients had oropharyngeal cancer and 69 had non-oropharyngeal HNSCC and these populations were analysed separately. NLR was not associated to any clinicopathological variable. On univariate analysis, NLR showed associations with RFS and OS in both sub-populations. Multivariable analysis showed patients with NLR > 5 had shortened OS in both sub-populations but NLR > 5 only predicted RFS in oropharyngeal patients. Poor performance status predicted OS in both sub-populations and current smokers had shortened OS and RFS in non-oropharyngeal patients.

**Conclusions:** The results show patients with NLR > 5 predict for shorter overall survival. Further prospective validation studies in larger cohorts are required to determine the clinical applicability of NLR for prognostication in HNSCC patients.

**Keywords:** Systemic inflammation, Prognosis, Head and neck cancer, Neutrophil-to-lymphocyte ratio, Overall survival, Recurrence free survival

* Correspondence: Thomas.Eade@health.nsw.gov.au
  Kellie A Charles and Benjamin DW Harris share the first authorship.
  ²Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
  ³Northern Clinical School (Medicine), University of Sydney, Sydney, NSW 2006, Australia
  Full list of author information is available at the end of the article

© 2016 Charles et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease and is the sixth most common cancer worldwide, with approximately 650,000 cases diagnosed worldwide annually and nearly 400,000 deaths [1, 2]. HNSCC encompasses a wide variety of malignancies deriving from the mucosal epithelium of the upper aerodigestive tract, including lip, oral cavity, paranasal sinuses, nasal cavity, pharynx and larynx [3]. Data from the USA indicates over two-thirds of patients present with advanced-stage disease with either locoregional spread to the lymph nodes or distant metastasis [4]. Historically, up to 50% of patients will experience locoregional recurrence within 2 years of treatment with limited options for salvage surgery or reirradiation [4, 5]. To date, there is limited molecular characterisation of the driver mutations of the various subtypes of HNSCC, with human papilloma virus (HPV), smoking and alcohol the only identified causative agents. Therefore, understanding the biological mechanisms that lead to cancer progression and identification of prognostic factors are essential to improve the clinical management of HNSCC.

A hallmark of many cancers, including HNSCC, is the presence of a tumour promoting phenotype of chronic, low-grade cancer-related inflammation [6–8]. Recent studies have demonstrated that cancer-related inflammation derives from communication between the host and tumour cells to develop a reciprocal interplay that often results in systemic alterations, immune suppression and evasion and malignant progression [6]. In HNSCC, cancer-related inflammation is characterised by increased circulating concentrations of pro-inflammatory cytokines and acute phase reactant proteins (C-reactive protein, serum amyloid A protein) that enhance the recruitment of circulating neutrophils, monocytes [9], myeloid derived suppressor cells (MDSC) [10, 11], and thus total leucocyte numbers, whilst also inhibiting the recruitment of lymphocytes to the circulation. These changes lead to the development of cancer-related syndromes, including fever, night sweats, fatigue, cachexia and bone and muscle pain [12].

Over the last few years, there has been a proliferation in clinical studies measuring the systemic inflammatory response in cancer patients to identify patients with poor prognosis (reviewed in [7, 13]). One of the key biomarkers of systemic inflammation is the neutrophil-to-lymphocyte ratio (NLR). An NLR score is obtained from a patients full blood count by dividing the absolute neutrophil count by the absolute lymphocyte count. An elevated NLR is strongly related to other inflammatory markers, including the Glasgow Prognostic Score, platelet-lymphocyte ratio and elevated C-reactive protein levels, which have been associated with increased tumour burden and spread of disease. NLR is elevated in patients with laryngeal squamous cell carcinoma compared to patients with benign and precancerous lesions [14]. NLR is also an independent prognostic marker of reduced overall survival (OS) in most epithelial cancers [6, 15].

There have been numerous studies of the prognostic role of NLR in various selected populations of HNSCC. Small studies conducted in site-specific populations of nasopharyngeal, oropharyngeal and oral cavity cancers, showed elevated NLR was predictive of local and regional recurrence or reduced progression free survival and/or poorer OS [16–20]. Investigations in small cohorts of unselected HNSCC patients have shown that HNSCC patients have an elevated NLR compared to healthy controls and univariate analyses have associated elevated NLR to recurrence, tumour and nodal stage [21–23]. A pilot study in 46 unselected HNSCC patients was conducted by our group and univariate analysis found that NLR was predictive of shorter overall survival [24]. However, in these investigations of heterogeneous populations of HNSCC, multivariable analysis of NLR as prognostic of recurrence free survival (RFS) or OS was not undertaken.

Additionally, literature shows that HPV mediated over-expression of p16 is an important marker of reduced risk for recurrence and survival in HNSCC [25, 26]. Recent in vitro and animal studies of cervical cancer have shown that HPV positive (HPV+) cells are more efficient at producing a pro-inflammatory tumour microenvironment [27] leading to enhanced myeloid cell proliferation in the bone marrow and spleen and increased recruitment of leucocytes to the tumour [28]. Thus, the p16 status of a patient may also alter the inflammatory response and contribute both directly and indirectly to cancer outcomes. Huang et al. [9] identified that p16 positive oropharyngeal cancer patients with high circulating neutrophil levels have a reduced OS and RFS. Interestingly, this association was not seen in the p16 negative oropharyngeal patients. Furthermore, higher levels of circulating lymphocytes were predictive of improved RFS and marginally improved OS in the p16 positive population but not in the p16 negative patients. Additionally, in a study by Ward et al. [29], HPV+ oropharyngeal cancer patients with high or moderate tumour infiltrating lymphocyte expression had significantly improved survival compared to HPV+ low tumour infiltrating lymphocytes and HPV negative (HPV-) patients regardless of lymphocyte expression. This would suggest within the HPV+ oropharyngeal cancer population the systemic and local inflammatory environment may be important for determination of clinical outcomes. In both studies there is a significant minority of HPV+ patients (20%) that have poor OS. Identification of this high risk group is important in an era of potential treatment de-escalation and introduction of molecularly targeted therapies. In addition, systemic inflammation has not been well investigated as predictive biomarker for all clinical outcomes in the non-oropharyngeal cancer...
population and identification of the high risk group of patients is also essential.

In this retrospective analysis, we sought to investigate whether NLR was an independent prognostic factor of RFS and OS in a prospectively collected, non-selected HNSCC population from one treatment centre. In addition we investigated whether elevated NLR was associated with clinicopathological features, including p16 status, which may aid in treatment decisions.

Methods
Study design
The Northern Sydney Local Health District Human Research Ethics Committee approved this study (1202-056 M). Following local institutional ethical review board approval, we conducted a retrospective analysis of patients with HNSCC treated at the Northern Sydney Cancer Centre between January 2005 and January 2012. Patients were identified using a prospectively collected Head and Neck Cancer Database [30] and informed written consent was obtained from all patients. Eligible patients were required to be 18 years or older, have pathologically confirmed primary mucosal squamous cell carcinoma, undergone radiotherapy based treatment, a minimum follow-up of 12 months (unless deceased) and NLR recorded within 30 days prior to commencing radiotherapy. The patient population included 145 patients with mucosal squamous cell carcinoma of the lip and oral cavity, oropharynx, hypopharynx, nasopharynx or larynx staged I-IV, who had been treated with radiotherapy alone or in combination with surgery and/or chemotherapy.

All patients were initially reviewed at a multidisciplinary head and neck tumour board, which included otorhinolaryngology surgeons, radiation oncologists and medical oncologists who assigned the tumour stage and subsequent management. The patient demographics collected for the present study included age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), smoking status (current, ex-smoker or non-smoker), primary tumour location, American Joint Committee on Cancer (AJCC; 6th Ed 2002) stage and treatment plan. Additionally, radiotherapy dose, number of fractions and the start and end date of radiotherapy were recorded for each patient. The pre-treatment neutrophil and lymphocyte counts were obtained and the NLR calculated by dividing the neutrophil count by the lymphocyte count. A cut-off of 5 was used to categorise patients with high (NLR > 5) or low (NLR ≤ 5) systemic inflammation. This cut-off was chosen based on the systematic review of the NLR literature in cancer which showed NLR > 5 as a predictive marker of cancer outcomes in over 30 studies of 15,500 cancer patients [7]. When available, immunohistochemistry for p16 was performed on formalin fixed paraffin embedded sections using a specific mouse monoclonal antibody (clone JC8, cat SC-56330, Santa Cruz CA, USA) at a dilution of 1 in 10. Staining was interpreted by two observers (TD, AJG) that were blinded to all other clinical and pathological details. Diffuse, strong, full thickness staining was categorised as p16 positive, while absent or focal staining was categorised as p16 negative.

All procedures were in accordance with the ethical standards of the institutional Human Research Ethics Committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.

Treatment
Patients were treated on a standard department protocols [30] either definitively with radiotherapy (stage I-II), chemoradiotherapy (stage III-IV) or postoperatively in high risk patients. Except for small field larynx treatments, radiotherapy was delivered with sliding window intensity modulated radiation therapy or volumetric modulated arc therapy. For definitive patients treated with chemoradiotherapy, the dose was 70 Gray (Gy) in 35 fractions with weekly cisplatin (40 mg/m²) and 63 Gy and 56 Gy respectively to the intermediate and low dose planning target volumes. For patients treated with radiotherapy alone either this fractionation was used or a hypofractionated schedule of 66 Gy in 30 fractions [31]. Postoperative patients received 60 Gy in 30 fractions. Treatment regimens provided to patients remained consistent over the study period.

Statistical analysis
The primary objective of the study was to determine whether NLR was a predictor of RFS and OS. Patients with oropharyngeal cancer were analysed separately from other tumour sites (lip and oral cavity, nasopharynx, hypopharynx and larynx) due to known difference in disease etiology and patients were assessed for differences between these sub-populations. Additionally, patient demographics were compared between p16 positive and negative oropharyngeal patients. Patient demographics were also assessed for differences in NLR status (NLR ≤ 5 vs NLR > 5) in the total population and the two sub-populations. Statistical tests used for the aforementioned univariate analyses included independent samples t-test or Mann Whitney-U test for continuous variables and χ² test or Fisher’s exact test for categorical variables.

Survival outcomes were determined from the start of radiotherapy until the date of the event or death from any cause (date of death obtained from hospital records). The exploratory variables analysed in univariate and multivariable survival analysis were assessed as follows: age (continuous or categorised into 4 groups with equal number of events for univariate survival analysis to assess linear trends), sex (male vs female), ECOG PS (0 vs 1 or 2), smoking (current smokers compared to non-smokers and ex-smokers), AJCC stage (I or II vs III or
IV), treatment (chemotherapy used vs other treatments), and NLR (≤5 vs >5). Patients who had surgery before anti-cancer treatment were not compared to non-surgical patients as surgeries were performed at multiple hospital sites and various types of surgeries were performed depending on the type of HNSCC. Additionally, surgical risk factors were initially included, but due to small numbers subsequently dropped from the analysis. Variables were assessed with Kaplan Meier log rank test and any variable with \( p \) value < 0.25 was included in a final multivariable Cox regression model to determine significant predictors of RFS and OS with adjustment from other exploratory variables. All data from survival analysis presented as hazard ratios (HR) ± 95 % confidence interval (CI). Statistical tests were two sided with a significance level of 0.05, and \( p \) values were not adjusted for multiple comparison testing. All analyses performed using IBM SPSS for Windows, Version 20.

**Results**

**Patient demographics for total population**

A total of 145 patients were included in this retrospective study and patient demographics are detailed in Table 1. This is an expanded dataset that includes 40 patients from a previous pilot study [24]. The median age was 63 years (range, 28–86 years) and the majority of patients were male (79 %) and most had ECOG PS 0 (70 %) or 1 (22 %). Some patients continued smoking through their treatment (26 %) but the majority were ex-smokers (42 %) or non-smokers (30 %). The most common primary disease site was oropharynx (52 %) and the majority of patients had AJCC stage III or IV disease (70 %). Patients were treated with definitive radiotherapy (12 %), postoperative radiotherapy (20 %), definitive chemoradiotherapy (61 %), or postoperative chemoradiotherapy (8 %). Of the 99 patients treated with chemotherapy 89 received weekly cisplatin, 8 received cetuximab and one received carboplatin. Weekly cisplatin was delivered for a median of 6 cycles. One patient did not complete a minimum of 5 cycles of cisplatin and was changed to cetuximab due to toxicity. Radiation treatment was completed without unscheduled breaks in 98 % of patients. Median (range) of neutrophils and lymphocytes was 5.10 (1.10-11.90) and 1.60 (0.20-10.70) x 10⁹ cells/L respectively. And the median (range) of the calculated NLR was 1.60 (0.20-10.70) for the total population. Material for p16 staining was available from 95 of 145 patients (66 %) patients. Systemic inflammation, as determined by elevated NLR >5, was observed in 20 % of patients. Of the 145 patients in this study, 37 patients (26 %) developed a recurrence or metastasis. At the end of the study, there were 35 deaths and a median 1-year OS of 91 %. Median follow-up time of patients was 29 months (range, 42 days to 7 years).

**Comparison of demographics between oropharyngeal patients and other primary sites**

Table 1 also shows differences between oropharyngeal cancer patients and other primary sites (classified as non-oropharyngeal cancer patients). Patients with oropharyngeal cancer were significantly younger (\( p < 0.01 \)) and had a better ECOG PS (\( p < 0.001 \)). There was a trend that showed oropharyngeal patients had more limited tumours (T1 or T2, 70 % vs 49 %), but more extensive nodal metastases (N2 or N3, 57 % vs 32 %). Therefore, there was no significant difference in final AJCC stage (\( p = 0.2 \)). Oropharyngeal patients rarely had surgery (7 % vs 55 %) and a higher proportion of patients received chemoradiotherapy (82 % vs 52 %). There were no differences in neutrophil and lymphocyte counts in either sub-group. Additionally, systemic inflammation was similar between both populations (NLR >5, 21 % vs 19 %, \( p = 0.7 \)). Finally, oropharyngeal patients were significantly more likely to show a positive p16 status (84 % vs 20 %, \( p < 0.001 \)).

In the oropharyngeal cancer patients with suitable tissue available for testing, 37 out of 44 tested p16 positive (84 %). This high percentage is consistent with the prevalence of p16 positivity in oropharyngeal patients over the last 5 years at this hospital site (data not shown). Due to the low numbers of p16 negative cases in the oropharyngeal cohort, it was deemed statistically invalid to investigate relationships between NLR and p16 status. Additionally, as the majority of patients were p16 positive there is limited utility for the use of this marker in oropharyngeal populations and, furthermore, there were no significant differences in patient demographics between p16 tested and non-tested oropharyngeal cancer cases (Additional file 1: Table S1). Therefore, in subsequent analysis we combined all oropharyngeal patients and excluded p16 status. In the non-oropharyngeal cancer patients 10 out of 51 tested patients were p16 positive (20 %) with variable rates for each major primary site (lip and oral cavity 4/9 (21 %), nasopharynx 1/1 (50 %), hypopharynx 0/9 (0 %) and larynx 5/21 (24 %)). Due to the lack of consistent evidence for p16 status as a predictive biomarker in non-oropharyngeal cancers and low numbers in each cancer subsite, we have also excluded p16 status from further analysis with clinical outcomes.

**NLR associations with patient demographics and survival**

NLR associations to patient demographics in the total population and oropharyngeal and non-oropharyngeal sub-populations are detailed in Table 2. NLR was not associated with age, sex, ECOG PS, smoking status, tumour site, tumour stage, nodal stage, AJCC stage or modality of treatment for any population. Neutrophils, lymphocytes and NLR were significantly associated with NLR status as expected (all \( p \) values < 0.01).
Table 1 Patient demographics

| Characteristic                        | All patients (N = 145)* | Oropharyngeal (n = 76)* | Non-oropharyngeal (n = 69)* | p value* |
|--------------------------------------|-------------------------|-------------------------|-----------------------------|----------|
| Age, median years (range)            | 63 (28–86)              | 59.5 (32–83)            | 67 (28–86)                  | <0.01    |
| Sex, n (%)*                          |                         |                         |                             | 0.5      |
| Male                                 | 115 (79)                | 62 (82)                 | 53 (77)                     |          |
| Female                               | 30 (21)                 | 14 (18)                 | 16 (23)                     |          |
| ECOG PS, n (%)                       |                         |                         |                             | <0.001   |
| 0                                    | 102 (70)                | 64 (84)                 | 38 (55)                     |          |
| 1                                    | 32 (22)                 | 10 (13)                 | 22 (32)                     |          |
| 2                                    | 10 (7)                  | 2 (3)                   | 8 (12)                      |          |
| Missing                              | 1 (1)                   | -                       | 1 (1)                       |          |
| Smoking status, n (%)                |                         |                         |                             | 0.2      |
| Non-smoker                           | 44 (30)                 | 24 (32)                 | 20 (29)                     |          |
| Ex-smoker                            | 61 (42)                 | 36 (47)                 | 25 (36)                     |          |
| Current smoker                       | 37 (26)                 | 15 (20)                 | 22 (32)                     |          |
| Missing                              | 3 (2)                   | 1 (1)                   | 2 (3)                       |          |
| Tumour site, n (%)                   |                         |                         |                             | <0.001   |
| Lip and oral cavity                  | 25 (17)                 | 0 (0)                   | 25 (36)                     |          |
| Nasopharynx                          | 8 (6)                   | 0 (0)                   | 8 (12)                      |          |
| Oropharynx                           | 76 (52)                 | 76 (100)                | 0 (0)                       |          |
| Hypopharynx                          | 12 (8)                  | 0 (0)                   | 12 (17)                     |          |
| Larynx                               | 24 (17)                 | 0 (0)                   | 24 (35)                     |          |
| Tumour stage, n (%)                  |                         |                         |                             | 0.05     |
| T1                                   | 35 (24)                 | 24 (32)                 | 11 (16)                     |          |
| T2                                   | 52 (36)                 | 29 (38)                 | 23 (33)                     |          |
| T3                                   | 36 (25)                 | 15 (19)                 | 21 (30)                     |          |
| T4                                   | 22 (15)                 | 8 (11)                  | 14 (20)                     |          |
| Nodal stage, n (%)                   |                         |                         |                             | <0.001   |
| N0                                   | 44 (30)                 | 11 (14)                 | 33 (48)                     |          |
| N1                                   | 36 (25)                 | 22 (29)                 | 14 (20)                     |          |
| N2                                   | 60 (41)                 | 41 (54)                 | 19 (28)                     |          |
| N3                                   | 5 (3)                   | 2 (3)                   | 3 (4)                       |          |
| AJCC stage, n (%)                    |                         |                         |                             | 0.2      |
| I                                    | 9 (6)                   | 4 (5)                   | 5 (7)                       |          |
| II                                   | 35 (24)                 | 18 (24)                 | 17 (25)                     |          |
| III                                  | 74 (51)                 | 44 (58)                 | 30 (43)                     |          |
| IV                                   | 27 (19)                 | 10 (13)                 | 17 (27)                     |          |
| p16 tumour status, n (%)             |                         |                         |                             | <0.001   |
| Negative                             | 48 (51)                 | 7 (16)                  | 41 (80)                     |          |
| Positive                             | 47 (49)                 | 37 (84)                 | 10 (20)                     |          |
| Missing                              | 50                      | 32                      | 19                          |          |
| Treatment, n (%)                     |                         |                         |                             | <0.001   |
| Radiotherapy                         | 17 (12)                 | 10 (13)                 | 7 (10)                      |          |
| Postoperative radiotherapy           | 29 (20)                 | 3 (4)                   | 26 (38)                     |          |
| Chemoradiotherapy                    | 88 (61)                 | 61 (80)                 | 27 (39)                     |          |
Univariate survival analysis showed NLR was associated to RFS and OS in the total heterogeneous population, oropharyngeal and non-oropharyngeal subpopulations. In the total population, patients with high NLR had significantly shorter RFS ($p < 0.01$) and OS ($p < 0.001$) and showed a shorter 1-year RFS and OS (62 % vs 87 % and 83 % vs 93 %, respectively). In the oropharyngeal sub-population, high NLR patients also showed a poorer RFS ($p < 0.01$) and OS ($p < 0.01$) with shorter 1-year RFS and OS (60 % vs 97 % and 94 % vs 98 %, respectively, Fig. 1a and c, Table 3). Similarly, non-oropharyngeal patients had a lower RFS ($p = 0.2$) and OS ($p < 0.01$) and shorter 1-year RFS and OS (62 % vs 77 % and 69 % vs 87 %, respectively, Fig. 1b, and d, Table 3).

**Predictors of recurrence free survival and overall survival**

Univariate survival analysis results for oropharyngeal and non-oropharyngeal populations are detailed in Table 3. These analyses showed that ECOG PS, smoking status and NLR associated to RFS and OS in both populations and were included in final Cox regression models as $p$ values were all less than 0.25. Additionally, age was associated with OS and RFS but only in the oropharyngeal population. Variables not associated with any survival outcome from univariate analysis included sex, AJCC stage and treatment modality. Sex was not analysed in oropharyngeal sub-population as no females had recurrence or died in the study period.

Multivariable analysis results are described in Table 3. In oropharyngeal patients, age was no longer associated with RFS or OS once adjusted for by other variables. However, patients with poorer ECOG PS (1 or 2) had a significantly increased hazard of death (4.4 (1.2-16.1), $p = 0.03$) and a trend for increased hazard of recurrence (2.9 (1.0-9.0), $p = 0.07$). Smoking status was not significantly predictive of OS and RFS in oropharyngeal patients. A high systemic inflammation status, NLR $> 5$, was significantly associated to increased hazard of death (4.6 (1.3-16.8), $p = 0.02$) and recurrence (3.0 (1.1-8.5), $p = 0.04$) in this sub-population.

In non-oropharyngeal patients, poor ECOG PS showed an increased hazard of death (2.6 (1.0-6.8), $p = 0.04$) but no association was seen for RFS. Non-oropharyngeal patients who continued to smoke through treatment had significantly increased hazard, compared to non-smokers and ex-smokers, for recurrence and death (both $p$ values $< 0.001$). An NLR $> 5$ was significantly associated with increased hazard of death (3.7 (1.3-9.9), $p = 0.02$) but no strong association to RFS was seen.

**Discussion**

NLR is an easily obtainable, inexpensive marker of systemic inflammation that may assist in clinical decisions regarding recurrence and survival in a heterogeneous HNSCC population. This study aimed to investigate the predictive role of NLR in an unselected population of HNSCC patient, but we found that oropharyngeal patients had significant differences in baseline characteristics compared to non-oropharyngeal patients. As expected from the growing literature, a very high percentage of oropharyngeal patients were p16 positive (84 %). Thus, we conducted total and sub-site analyses due to the differences reflecting the potential diverging molecular etiology of oropharyngeal and non-oropharyngeal disease. In univariate analysis, NLR status did not associate with any other clinicopathological variables other than neutrophil and lymphocyte levels in either subgroup as expected. Patients with an elevated NLR were associated with shorter RFS and OS in both oropharyngeal and non-oropharyngeal populations. Univariate survival analysis showed ECOG PS, smoking status, age and NLR associated with RFS and OS to varying degrees in both populations. Multivariable analysis confirmed NLR significantly predicted RFS in oropharyngeal patients only, while NLR strongly predicted OS in both sub-populations. Additionally, ECOG PS significantly showed associations to OS in oropharyngeal patients and non-oropharyngeal patients. Interestingly, smoking status remained predictive of RFS and OS only in non-oropharyngeal patients. This may not be unexpected considering the low numbers of p16 negative patients in

---

**Table 1 Patient demographics (Continued)**

|                          | Total $n$ | Oropharyngeal $n$ | Non-oropharyngeal $n$ |
|--------------------------|----------|-------------------|-----------------------|
| Postoperative chemoradiotherapy | 11 (8)   | 2 (3)             | 9 (13)                |
| Neutrophils, median counts (range) $\times 10^9$ cells/L | 5.10 (1.10 - 11.90) | 4.60 (1.10 - 11.90) | 5.30 (2.10 - 11.80) |
| Lymphocytes, median counts (range) $\times 10^9$ cells/L | 1.60 (0.20 - 10.70) | 1.60 (0.40 - 3.40) | 1.70 (0.20 - 10.70) |
| NLR, median counts (range) $\times 10^9$ cells/L | 3.11 (0.41 - 29.75) | 3.11 (1.30 - 29.75) | 3.11 (0.41 - 16.00) |

**Abbreviations**: ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer and NLR neutrophil-to-lymphocyte ratio

*appropriate statistical test (Students $t$-test, Mann Whitney-U, $\chi^2$ test or Fishers exact test) conducted between oropharyngeal and non-oropharyngeal cancer patient excluding missing values and *a, missing values indicated in table.
| Characteristic                  | All patients (N = 145)* | Oropharyngeal (n = 76)* | Non-oropharyngeal (n = 69)* |
|--------------------------------|-------------------------|-------------------------|----------------------------|
|                                | NLR ≤ 5 (n = 116) | NLR > 5 (n = 29) | p value* | NLR ≤ 5 (n = 60) | NLR > 5 (n = 16) | p value* | NLR ≤ 5 (n = 56) | NLR > 5 (n = 13) | p value* |
| Age, median years (range)      | 61 (32–86) | 67 (28–86) | 0.2 | 57.5 (32–83) | 64 (47–81) | 0.07 | 65 (38–86) | 70 (28–86) | 0.8 |
| Sex, n (%)                     | 1 | 1 | | 13 (81) | 13 (23) | 3 (23) | | | |
| Male                           | 92 (79) | 23 (79) | 0.2 | 49 (82) | 13 (81) | | 43 (77) | 10 (77) | |
| Female                         | 24 (21) | 6 (21) | | 11 (18) | 3 (19) | | 13 (23) | 3 (23) | |
| ECOG PS, n (%)                 | | | | 0.3 | | | | | |
| 0                              | 84 (73) | 18 (62) | | 51 (85) | 13 (81) | 0.3 | 33 (60) | 5 (38) | |
| 1                              | 24 (21) | 8 (28) | 0.07 | 8 (13) | 2 (13) | | 16 (29) | 6 (46) | |
| 2                              | 7 (6) | 3 (10) | 0.07 | 1 (2) | 1 (6) | 0.8 | 6 (11) | 2 (15) | |
| Smoking status, n (%)          | | | | 0.4 | | | | | |
| Non-smoker                     | 35 (31) | 9 (32) | | 19 (32) | 5 (31) | | 16 (29) | 4 (33) | |
| Ex-smoker                      | 48 (42) | 13 (46) | | 29 (49) | 7 (44) | | 19 (35) | 6 (50) | |
| Current smoker                 | 31 (27) | 6 (21) | | 11 (19) | 4 (25) | | 20 (36) | 2 (17) | |
| Tumour site, n (%)             | | | | 0.6 | | | | | |
| Lip and oral cavity            | 20 (17) | 5 (17) | | 0 (0) | 0 (0) | | 20 (36) | 5 (38) | |
| Nasopharynx                    | 8 (7) | 0 (0) | | 0 (0) | 0 (0) | | 8 (14) | 0 (0) | |
| Oropharynx                     | 60 (52) | 16 (55) | | 60 (100) | 16 (100) | | 0 (0) | 0 (0) | |
| Hypopharynx                    | 9 (8) | 3 (10) | | 0 (0) | 0 (0) | | 9 (16) | 3 (23) | |
| Larynx                         | 19 (16) | 5 (17) | | 0 (0) | 0 (0) | | 19 (34) | 5 (38) | |
| Tumour stage, n (%)            | | | | 0.8 | | | | | |
| T1                             | 31 (27) | 4 (14) | | 22 (37) | 2 (13) | | 9 (16) | 2 (15) | |
| T2                             | 38 (33) | 14 (48) | | 21 (35) | 8 (50) | | 17 (30) | 6 (46) | |
| T3                             | 29 (25) | 7 (24) | | 11 (18) | 4 (25) | | 18 (32) | 3 (23) | |
| T4                             | 18 (16) | 4 (14) | | 6 (10) | 2 (13) | | 12 (21) | 2 (15) | |
| Nodal stage, n (%)             | | | | 0.3 | | | | | |
| N0                             | 37 (32) | 7 (24) | | 10 (17) | 1 (6) | | 27 (48) | 6 (46) | |
| N1                             | 26 (22) | 10 (35) | | 17 (28) | 5 (31) | | 9 (16) | 5 (38) | |
| N2                             | 48 (41) | 12 (41) | | 31 (52) | 10 (63) | | 17 (30) | 2 (15) | |
| N3                             | 5 (4) | 0 (0) | | 2 (3) | 0 (0) | | 3 (5) | 0 (0) | |
| AJCC stage, n (%)              | | | | 0.5 | | | | | |
| I                              | 7 (6) | 2 (7) | | 4 (7) | 0 (0) | | 3 (5) | 2 (15) | |
| II                             | 27 (23) | 8 (28) | | 14 (23) | 4 (25) | | 13 (23) | 4 (31) | |
| III                            | 59 (51) | 15 (52) | | 34 (57) | 10 (63) | | 25 (45) | 5 (38) | |

*Charles et al. BMC Cancer (2016) 16:124
Table 2 Differences in clinical characteristics for high and low NLR groups (Continued)

| IV                      | High NLR (n=100) | Low NLR (n=100) | p       | High NLR (n=150) | Low NLR (n=150) | p       | High NLR (n=200) | Low NLR (n=200) | p       |
|-------------------------|------------------|-----------------|--------|------------------|-----------------|--------|------------------|-----------------|--------|
| p16 tumour status, n (%)|                  |                 | 0.8    | 0.6              | 0.2             |        | 0.8              | 0.2             |        |
| Negative                | 39 (51)          | 9 (47)          |        | 5 (14)           | 2 (25)          |        | 34 (85)          | 7 (64)          |        |
| Positive                | 37 (49)          | 10 (53)         |        | 31 (86)          | 6 (75)          |        | 6 (15)           | 4 (36)          |        |
| Treatment, n (%)        | 0.8              |                 | 0.8    | 0.8              | 0.8             |        | 0.8              | 0.8             |        |
| Radiotherapy            | 14 (12)          | 3 (10)          |        | 9 (15)           | 1 (6)           |        | 5 (9)            | 2 (15)          |        |
| Postoperative radiotherapy | 24 (21)        | 5 (17)          |        | 3 (5)            | 0 (0)           |        | 21 (38)          | 5 (38)          |        |
| Chemoradiotherapy       | 68 (59)          | 20 (69)         |        | 46 (77)          | 15 (94)         |        | 22 (39)          | 5 (38)          |        |
| Postoperative chemoradiotherapy | 10 (9)     | 1 (3)           |        | 2 (3)            | 0 (0)           |        | 8 (14)           | 1 (8)           |        |
| Neutrophils, median counts (range) | 4.55 (1.10-11.80) | 6.80 (3.2-11.90) | <0.001 | 4.40 (1.10-9.30) | 7.85 (3.90-11.90) | <0.001 | 5.15 (2.10-2.80) | 6.50 (3.20-11.80) | <0.01 |
| Lymphocytes, median counts (range) | 1.75 (0.50-10.70) | 1.10 (0.20-1.70) | <0.001 | 1.65 (0.50-3.40) | 1.10 (0.40-1.70) | <0.001 | 1.90 (0.60-10.70) | 1.00 (0.20-1.50) | <0.001 |
| NLR, median counts (range) | 2.69 (0.41-5.00) | 6.71 (5.09-29.75) | <0.001 | 2.71 (1.30-4.78) | 6.41 (5.09-29.75) | <0.001 | 2.64 (0.41-5.00) | 7.00 (5.55-16.00) | <0.001 |

Abbreviations: NLR neutrophil-to-lymphocyte ratio, ECOG PS Eastern Cooperative Oncology Group performance status and AJCC American Joint Committee on Cancer
* appropriate statistical test (Students t-test, Mann Whitney-U, χ² test or Fishers exact test) conducted between high and low NLR patients and *, missing values excluded from table and statistical analysis
the oropharyngeal cancer cohort, which may represent the contribution of smoking habits in the causation of disease in these patients.

The majority of oropharyngeal patients were p16 positive in this study and oropharyngeal patients were younger, had better ECOG PS but had increased nodal spread compared to non-oropharyngeal patients. Eighty-four percent of tested oropharyngeal patients had p16 positive tumours. This percentage is comparable to other American, Swedish and British studies (summarised in [32]) although higher than the average rate (~40 %) in most developed countries. Patients with p16 positive tumours are generally younger [33] and have been noted to have better ECOG PS and higher nodal stages when compared to p16 negative patients [34, 35]. The high prevalence of p16 in the oropharyngeal population most likely accounts for the younger age and better ECOG PS compared to non-oropharyngeal patients seen in this study. The higher nodal stage but improved outcomes in p16 positive patients is the most likely cause of AJCC stage not being significant in our study, similar to other reports [34]. The 3-year OS of oropharyngeal patients was 86 % and 69 % for p16 positive and negative patients respectively, which is comparable to larger studies [36–38]. In vitro studies with p16 positive HNSCC cells lines have shown that these cells are more radiosensitive [39]. Oropharyngeal patients in our unit are unlikely to undergo primary surgical intervention due to the perceived high risk of morbidity if extensive surgery is required. Our excellent rates of locoregional control in this population further support this recommendation. However with availability of transoral robotic assisted surgery [40], a biomarker to predict a poor performing oropharyngeal subgroup may aid selection of patients for surgery in the future.

With decreasing smoking rates due to extensive anti-smoking campaigns, as seen in countries such as Australia, HPV+ oropharyngeal cancer is increasingly becoming the prominent subtype. Therefore, additional predictive

---

**Fig. 1** Association of neutrophil-to-lymphocyte ratio to survival outcomes. Neutrophil-to-lymphocyte ratio association to recurrence free survival in oropharyngeal (a) and non-oropharyngeal (b) patients. Neutrophil-to-lymphocyte ratio association to overall survival in oropharyngeal (c) and non-oropharyngeal (d) patients. Abbreviations: RFS, recurrence free survival; NLR, neutrophil-to-lymphocyte ratio and OS, overall survival.
biomarkers of clinical outcomes are needed within the HPV+ or p16 positive oropharyngeal cancer population. Additionally, classification of patients as HPV+ is not without difficulty as the various techniques of assessment produce variable results and there is no universally agreed classification system. The results of this study show that on a background of high p16 positive status, elevated NLR was associated with recurrence and survival outcomes under univariate analysis and many of the recurrences and deaths occurred within the first year following radiotherapy. Multivariable analysis showed that NLR remained a predictor of OS independent of AJCC stage, tumour site, treatment modality and sex in oropharyngeal and non-oropharyngeal sub-populations. Additionally, NLR also predicted RFS in oropharyngeal patients. The results of this study identified NLR as a prognostic marker of OS in an unselected HNSCC cohort, supporting previous findings from other studies in nasopharyngeal, oral squamous cell carcinoma and preliminary investigations in unselected HNSCC cohorts [14, 16–22, 41]. These findings are also consistent with other cancer types including other head and neck associated cancers, such as thyroid cancer [42, 43]. The association between NLR and poor OS and recurrence is not well understood. However, it is hypothesised that elevated NLR reflects a more aggressive tumour phenotype that is immune evasive and/or suppressive. Elevated NLR is more often seen in patients with advanced disease, as denoted by increased AJCC stage, tumour depth of invasion or metastatic spread [7]. In our study, we did not find evidence to confirm NLR was associated with higher AJCC staging and thus may represent aspects reflecting immune suppression. Recent analysis conducted by The Cancer Genome Atlas project, shows that within the HPV+ population of HNSCC there is an increase in loss of TNF receptor-associated factor 3 gene and presence of activating mutations in PIK3CA gene, which enhance NF-κB signalling and promote a pro-inflammatory micro-environment [44]. This data supports the role of cancer-related inflammation in determining the outcomes of HPV+ HNSCC patients.

### Table 3

| Variable | Overall survival | Recurrence free survival |
|----------|-----------------|-------------------------|
|          | Univariate, HR (95 % CI) | p value* | Multivariable, HR (95 % CI) | p value** | Univariate, HR (95 % CI) | p value* | Multivariable, HR (95 % CI) | p value** |
|----------|-----------------|---------|-----------------|---------|-----------------|---------|-----------------|---------|
| Oropharyngeal patients (n = 76)* | | | | | | | | |
| Age (continuous) | 1.07 (1.01-1.12) | 0.03 | 1.03 (0.97-1.10) | 0.3 | 1.05 (1.00-1.10) | 0.08 | 1.02 (0.97-1.08) | 0.4 |
| Sex (males vs females) | No females died | | | | | | | |
| ECOG PS (0 vs 1–2) | 4.08 (1.38-12.12) | <0.01 | 4.36 (1.18-16.06) | 0.03 | 3.33 (1.24-8.89) | 0.01 | 2.92 (0.95-8.97) | 0.07 |
| Smoking status | <0.01 | | 0.2 | | | | | |
| (current smoker vs non-smoker) | 0.17 (0.04-0.70) | 0.34 (0.07-1.64) | 0.01 | 0.31 (0.01-0.98) | 0.53 (0.15-1.88) | 0.02 | 0.28 (0.09-0.85) | 0.40 (0.12-1.31) |
| (current smoker vs ex-smoker) | 0.22 (0.07-0.80) | 0.28 (0.07-1.09) | 0.15 | 0.31 (0.01-0.98) | 0.53 (0.15-1.88) | 0.02 | 0.28 (0.09-0.85) | 0.40 (0.12-1.31) |
| AJCC stage (I-II vs III-IV) | 0.78 (0.26-2.34) | 0.7 | | | | | | |
| Treatment (CRT and CRT + surgery vs RT and RT + surgery) | 0.50 (0.46-4.93) | 0.5 | | | | | | |
| NLR (≤ 5 vs > 5) | 4.96 (1.66-14.80) | <0.01 | 4.60 (1.26-16.80) | 0.02 | 3.50 (1.38-8.90) | <0.01 | 3.01 (1.07-8.45) | 0.04 |
| Non-oropharyngeal patients (n = 69)c | | | | | | | | |
| Age (continuous) | 1.02 (0.99-1.06) | 0.8 | | | | | | |
| Sex (males vs females) | 1.05 (0.38-2.87) | 0.9 | | | | | | |
| ECOG PS (0 vs 1–2) | 3.37 (1.36-8.37) | <0.01 | 2.57 (0.98-6.76) | 0.04 | 1.66 (0.82-3.36) | 0.2 | 1.49 (0.70-3.21) | 0.2 |
| Smoking status | 0.04 | <0.001 | 0.02 | | | | | |
| (current smoker vs non-smoker) | 0.18 (0.04-0.79) | 0.16 (0.03-0.76) | 0.35 | 0.35 (0.14-0.90) | 0.35 (0.14-0.90) | 0.35 (0.14-0.90) | 0.35 (0.14-0.90) | 0.35 (0.14-0.90) |
| (current smoker vs ex-smoker) | 0.56 (0.22-1.44) | 0.34 (0.12-0.94) | 0.38 | 0.16-0.90) | 0.32 (0.13-0.79) | 0.32 (0.13-0.79) | 0.32 (0.13-0.79) | 0.32 (0.13-0.79) |
| AJCC stage (I-II vs III-IV) | 1.43 (0.56-3.70) | 0.5 | | | | | | |
| Treatment (CRT and CRT + surgery vs RT and RT + surgery) | 0.85 (0.46-2.57) | 0.8 | | | | | | |
| NLR (≤ 5 vs > 5) | 3.32 (1.36-8.10) | <0.01 | 3.64 (1.34-9.87) | 0.02 | 1.76 (0.79-3.96) | 0.2 | 2.02 (0.83-4.91) | 0.1 |

**Abbreviations:** HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer, CRT chemoradiotherapy, RT radiotherapy and NLR neutrophil-to-lymphocyte ratio

* p value from Kaplan-Meier logrank test; ** p value from Cox regression log likelihood ratio test; a, one patient missing smoking status; b, referent group; and c, missing 3 patients (two patients missing smoking status and one patient missing ECOG status).
In the tumour microenvironment, innate immune cells, such as neutrophils, macrophages and myeloid derived suppressor cells, regulate both immune surveillance and suppression [45]. Increased abundance of these cells is observed in more advanced stages of HNSCC and is associated with poorer survival [9–11, 46]. Mechanistic studies conducted in animal models and ex vivo cultures of immune cells from HNSCC patients have demonstrated that myeloid derived suppressor cells are critical for regulating the immunosuppressive phenotype and function of cooperating lymphoid-derived cells in the tumour and circulation [10, 11, 47, 48]. In terms of adaptive immune cells, the low infiltration of T cells, particularly T regulatory cells, combined with functional deficits in T helper cells, cytotoxic T cells and natural killer cells leads to the highly immune suppressive tumour microenvironment that allows for unrestrained tumour growth [29, 49–52].

Improved understanding of the various interactions of the tumour and immune system suggest that the ideal biomarker would measure both the innate and adaptive immune response, such as the NLR, as this may provide a better indication of the impact of tumour growth on both arms of the host immune response. In a mixed cancer population (not including HNSCC patients) elevated NLR was found to positively correlate with circulating MDSC levels and suppression of lymphocyte function [53]. However, there is no evidence to date that specifically links elevated NLR to immune cell behaviour in HNSCC tumours or circulation. Unfortunately, we do not have blood samples from our patient cohort, but it would be interesting to investigate circulating NLR values in studies that have measured peripheral blood and tumoural MDSC or T cell populations and overall survival to clarify the biological relationships between NLR and immune suppression in cancer.

More recently, the NLR has been suggested as a Phase I clinical trial patient selection tool by the Royal Marsden Hospital, UK [54]. Pharmacological inhibitors of key immunosuppressive mediators (anti-PD1 or PD ligand 1 antibodies, STAT3 and PDE5 inhibitors) have been shown to reduce the number and function of MDSC, Tregs and/or immune T cell-mediated anti-tumour responses in mice and are increasingly being investigated in clinical trials [11, 55, 56]. New data from the The Cancer Genome Atlas [44] has also suggested novel pathways for intervention, such as the PIK3 pathway due to activating mutations in PIK3CA for HPV+ cancers. Thus, NLR could be useful as inclusion criteria for clinical trial participation investigating these molecular targeted and immune modulating therapies.

In addition to NLR predicting survival outcomes, other exploratory variables including smoking status and ECOG PS were predictive of RFS and OS. Smoking status was a significant predictor of RFS and OS but only in the non-oropharyngeal population. Smoking is not only a risk factor for the development of head and neck cancer but patients who maintain smoking during treatment are also at increased hazard of worse clinical outcomes [57]. Patients with poorer ECOG PS had an increased hazard of death in both sub-populations which has been suggested previously in HNSCC [58] and observed in other advanced cancers [59].

This study is limited by inherent selection bias due to the retrospective analysis of this study and being conducted in one metropolitan area hospital. However, this cohort reflects the heterogeneous nature of HNSCC in the community. Our population has a large proportion of p16 positive oropharyngeal tumours with comparable clinical outcomes to other international sites. Similar to other cancers (breast, colon, lung), the management of this patient group will change in the future from one single treatment to individualised treatments based on patient and tumour characteristics. One of the main limitations of the study was the incomplete analysis of p16 status in all patients. It would be of interest to investigate if the p16 positive oropharyngeal patients alone mimic the results of the total oropharyngeal population. Due to the high rates of positive patients it is probable that the results would be similar, unfortunately, our study did not have large enough numbers of tested patients to confirm this assumption. Although all patients had radiotherapy and chemotherapy at the one site, surgery was conducted over multiple hospital sites. Unfortunately, we were unable to collect diagnostic blocks from some surgical sites and private pathology laboratories. As such, we assumed based on the lack of significant differences in major covariates in the tested and untested populations and consistency with overall rates of p16 positive oropharyngeal cancer patients in our local area health service, that p16 status was not a statistically relevant covariate in our patient population. Using this assumption we may have missed an important interaction between p16 and NLR. In addition, we used p16 immunohistochemistry as the method for HPV positivity. There is a known discordance between DNA and protein detection methods [60, 61]. The p16 positive immunohistochemistry staining method, as performed in this paper, assumes that the over-expression of p16 is predominantly due to HPV infections, however HPV-independent mechanisms such as alterations in the retinoblastoma pathway may also drive p16 expression [44]. A variety of DNA-based and immunohistochemical methods have been used in various studies and consensus methods are being developed.

Conclusions
We have conducted an extensive analysis of clinicopathological variables and identified that NLR, ECOG PS and smoking status are predictive of OS and RFS in subpopulations of a heterogeneous HNSCC population. NLR
is an inexpensive, routinely available blood test based marker that would be a valuable tool for use in clinical decision-making. The association of NLR to RFS and OS is believed to relate to potential roles of inflammation in regulating cancer progression and immune evasion. Thus, NLR may help identify patients at high risk of recurrence and early death and indicates that this subset of patients may require additional treatments in order to improve their prognostic outcome. Additionally, the NLR has potential utility in selecting patient populations in clinical trials using immune modulating therapies. Further larger prospective studies are required in HNSCC populations to improve the clinical outcomes of all patients.

Additional file

**Additional file 1: Table S1.** Patient demographic differences between p16 tested and non-tested oropharyngeal patients. (XLSX 11 kb)

**Abbreviations**

AICC: American Joint Committee on Cancer; CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; FDG-PET: Fluorodeoxyglucose-positron emission tomography; G: Gray; HNSCC: Head and neck squamous cell cancer; HPV: Human papilloma virus; HR: Hazard ratio; MDSC: Myeloid derived suppressor cells; NLR: Neutrophil-to-lymphocyte ratio; OS: Overall survival; RFS: Recurrence free survival.

**Competing interest**

The authors declare that they have no competing interests.

**Authors’ contributions**

KC, SC and TE conceived the design of the study. CH, SC, AG, MS, MB, DV and CH were involved in data collection, data entry and clinical management. KC, SC and TE conceived the design of the study. CH, SC, AG, MS, MB, DV and TE were involved in data collection, data entry and clinical management of patients. TD and AUC interpreted immunohistochemistry staining. KC, BH, CH carried out statistical analysis. All authors contributed to data interpretation. All authors contributed to drafting and revising the final manuscript.

**Acknowledgements**

KC is supported by a Cancer Institute NSW Career Development Fellowship (#10/CDF/2-36).

**Author details**

1School of Medical Sciences (Pharmacology) and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia. 2Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. 3Northern Clinical School (Medicine), University of Sydney, Sydney, NSW 2006, Australia. 4Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. 5Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. 6Cancer Diagnosis and Pathology Research Group, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW 2006, Australia. 7Department of Surgery, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.

Received: 8 September 2015 Accepted: 28 January 2016

**Published online:** 18 February 2016

**References**

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v.1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. 2013. http://globocan.iarc.fr. Accessed 1 Sept 2015

2. Bray F, Ren J, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.

3. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008;113(7 Suppl):1911–32.

4. Angiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695–709.

5. Pignon JP, Le Maître A, Maillard E, Bouhis J, Grp M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):14–14.

6. Dakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.

7. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Curr Opin Oncol Hematol. 2013;20(1):218–30.

8. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–8.

9. Huang SH, Waldron JN, Milosevic M, Shen X, Ringash J, Su J, et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015;121(4):545–55.

10. Treflak S, Bruderek K, Hulter J, Elan M, Hoffmann TK, Lang S, et al. Granulocytic myeloid-derived suppressor cells are cytotoxic and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Inntimate. 2013;19(3):328–36.

11. Vazquez-Dunddel D, Pan F, Zeng Q, Gorbonov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-1 in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580–9.

12. Clarke SJ, Chua W, Moses M, Kao S, Phan V, Tan C, et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90(4):475–8.

13. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.

14. Krum RO, Ozcan M, Bakladl D, Kurn NY, Yilmaz YF, Gungor V, et al. Elevated neutrophil-to-lymphocyte ratio in squamous cell carcinoma of larynx compared to benign and precancerous laryngeal lesions. Asian Pac J Cancer Prev. 2014;15(17):7351–5.

15. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–95.

16. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol. 2011;32(2):237–24.

17. Fang HY, Huang XY, Chien HT, Chang JT, Liao CT, Huang JJ, et al. Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope. 2013;123(11):2690–9.

18. He JR, Shen GP, Ren ZF, Qin H, Cui C, Zhang Y, et al. Pre-treatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(12):1769–76.

19. Periasanis C, Korre J, Poschl PW, Holzinger D, Pirklbauer K, Schopper C, et al. High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol. 2013;30(1):334.

20. Young CA, Murray LJ, Karakaya E, Thygesen HH, Sen M, Prestwich RJ. The prognostic role of the neutrophil-to-lymphocyte ratio in oropharyngeal carcinoma treated with chemoradiotherapy. Clin Med Insights Oncol. 2014;8:1–6.

21. Trelak S, Bruderek K, Duymutra GA, Gholam H, Gu X, Bankfåvä E, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129(9):2183–93.

22. Millrud CR, Mansson Kvanhannam A, Uddman R, Björnsson S, Riesbeck K, Cardell LO. The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival. PloS One. 2012;7(12):e51120.

23. Rassouli A, Saliba J, Castano R, Hier M, Zeitouni AG. Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck. 2011;33(7):103–10.

24. Haddad CR, Guo L, Clarke S, Guimisins A, Back M, Eade T. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imaging Radiat Oncol. 2015;59(3):1754–548.

25. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

26. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al. p16 Protein Expression and Human Papillomavirus Status As Prognostic
34. Oguejiofor KK, Hall JS, Mani N, Douglas C, Slevin NJ, Homer J, et al. The
33. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human
32. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al.
31. Eisbruch A, Harris J, Garden AS, Chao CKS, Straube W, Harari PM, et al.
29. Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, et al.
28. Stone SC, Rossetti RA, Lima AM, Lepique AP. HPV associated tumor cells
treatment of locally advanced mucosal head and neck cancer outcomes from
a single-institution series. J Med Imaging Radiat Oncol. 2013;57(3):356–63.
27. Prabhavathy D, Vijayalakshmi R, Kanchana MP, Karunagaran D. HPV16 E2
enhances the expression of NF-kappaB and STAT3 target genes and
tumours. J Virol. 2014;88(21):11790–9.
25. Stone SC, Rossetti RA, Lima AM, Lepique AP. HPV associated tumor cells
treatment of locally advanced mucosal head and neck cancer outcomes from
a single-institution series. J Med Imaging Radiat Oncol. 2013;57(3):356–63.
24. Eisbruch A, Harris J, Garden AS, Chao CKS, Straube W, Harari PM, et al. Intensity-modulated
radiotherapy using simultaneous-integrated boost for definitive
treatment of locally advanced mucosal head and neck cancers: outcomes from
a single-institution series. J Med Imaging Radiat Oncol. 2013;57(3):356–63.
23. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al.
HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers:
a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31.
22. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human
papillomavirus type 16 and squamous cell carcinoma of the head and neck
Clin Cancer Res. 2003;9(18):5187–92.
21. Ogude forf JK, Hall JS, Mani N, Douglas C, Slevin NJ, Homer J, et al. The
prognostic significance of the biomarker p16 in oropharyngeal squamous
cell carcinoma. Clin Oncol (R Coll Radiol). 2013;25(11):630–8.
20. Maru S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck
cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.
19. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American
Joint Committee on Cancer/Union for International Cancer Control TNM
stage and prognostic groups for human papillomavirus-related oropharyngeal
carcinomas. J Clin Oncol. 2013;31(8):836–45.
18. Kim MJ, Ki MS, Kim K, Shim HJ, Hwang JE, Bae WK, et al. Different protein
expression associated with chemotherapy response in oropharyngeal cancer
according to HPV status. BMC Cancer. 2014;14:824.
17. Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ,
et al. Impact of HPV-associated p16-expression on radiotherapy outcome in
advanced oropharynx cancers. Radiother Oncol. 2014;113(3):310–6.
16. Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch CJ, Petersen C, et al. HNSCC
cells line positive for HPV and p16 possess higher cellular radiosensitivity
due to an impaired DSBR repair capacity. Radiother Oncol. 2013;107(2):242–6.
15. Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Luft F, et al. A
Contemporary Analysis of Surgical Trends in the Treatment of Squamous
Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the
National Cancer Database. Ann Surg Oncol. 2015;10:1255-456-x.
10. Rassoul A, Saliba J, Castano R, Hier M, Zeitouni AG. Systemic inflammatory
markers as independent prognosticators of head and neck squamous cell
carcinoma. Head Neck. 2015;37(3):500-506.
8. Liu CL, Lee JI, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-
lymphocyte ratio correlates with tumor size in patients with differentiated
tyroid cancer. J Surg Oncol. 2013;107(5):493–7.
7. Sereti C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil-to-lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroid goiters: a pilot study. Am J Surg. 2013;205(6):561-5.
6. The Cancer Genome Atlas Network. Comprehensive genomic
characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.
5. McEnrich B, Bindra G, Pages F, Galon J. Tumor immunosurveillance in human
cancers. Cancer Metastasis Rev. 2011;30(1):15–26.
4. Li C, Shintani S, Terakado N, Nakashiro K, Hamakawa H. Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma. Oncol Rep. 2002;9(6):1219–23.
3. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K. Immununospressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci. 2012;103(6):976–83.